All In Biotech

NDA 021774 · Cosette

Ambien Cr

Zolpidem Tartrate · Oral

Last checked: Nov 20, 2026Latest source record: Feb 23, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Sep 2, 2005

Approved uses

5

Original approval plus efficacy supplements

Registered trials

142

25 Phase 3, 8 recruiting

FAERS reports

86,212

54,394 serious, 7,465 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: COMPLEX SLEEP BEHAVIORS Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of Zolpidem Tartrate. Some of these events may result in serious injuries, including death. Discontinue Zolpidem Tartrate immediately if a patient experiences a complex sleep behavior [see Contraindications (4) and Warnings and Precautions (5.1) ]. WARNING: COMPLEX SLEEP BEHAVIORS See full prescribing information for complete boxed warning. Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of Zolpidem Tartrate. Some of these events may result in serious injuries, including death. Discontinue Zolpidem Tartrate immediately if a patient experiences a complex sleep behavior. ( 4 , 5.1 )

What it is approved for

From the label in effect Nov 19, 2025.

Zolpidem tartrate extended-release tablets is indicated for the short-term treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset). The clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient reported assessment in adult patients only) in duration [see Clinical Studies (14) ]. Zolpidem Tartrate, a gamma-aminobutyric acid (GABA) A receptor positive modulator, is indicated for the short-term treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. ( 1 )

Mechanism: Zolpidem is a GABA A receptor positive modulator presumed to exert its therapeutic effects in the short-term treatment of insomnia through binding to the benzodiazepine site of α1 subunit containing GABA A receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • AMBIEN CR · ZOLPIDEM TARTRATE 6.25MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • AMBIEN CR · ZOLPIDEM TARTRATE 12.5MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Zolpidem" as an intervention, any sponsor and status, largest first.

All 142 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea6,141
  • drug ineffective6,033
  • fatigue5,990
  • insomnia4,866
  • pain4,780
  • headache4,552
  • diarrhoea4,179
  • anxiety3,977
  • dizziness3,837
  • dyspnoea3,743
  • fall3,684
  • depression3,442

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,922
20052,500
20063,322
20073,220
20082,649
20093,416
20103,965
20113,704
20124,791
20133,999
20143,972
20156,134
20166,652
20174,956
20186,106
20194,674
20203,851
20212,891
20222,989
20232,726
20242,810
20252,867
20262,091

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ambien Cr (Zolpidem Tartrate)

2024 spending

$5.7M

Beneficiaries

1,218

7,083 claims

Per beneficiary

$4,640

$20.50 per unit

View as table
YearSpending
2020$7,662,023
2021$7,695,946
2022$5,838,739
2023$5,862,427
2024$5,651,298

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 490 on PubMed

Sponsor: Cosette

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.